livmoniplimab

{
  "id": "MLC-T-ONC-014857",
  "term": "livmoniplimab",
  "field": "Oncology and biomedicine",
  "definition": "A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator, glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, livmoniplimab selectively targets and binds to GARP which interferes with the production and release of active TGFbeta by regulatory T cells (Tregs). Selective inhibition of the release of TGFbeta from Tregs leads to a reversal of immunosuppression thereby increasing the immune response to tumor cells. GARP, a leucine-rich repeat-containing protein, is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function.",
  "synonyms": [
    "anti-glycoprotein A repetitions predominant monoclonal antibody ABBV-151",
    "anti-GARP monoclonal antibody ABBV-151"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/livmoniplimab/"
}